Stoke Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Stoke Therapeutics

03/08/2026 22:01

Stoke Therapeutics Inc STOK.OQ reported a quarterly adjusted loss of 93 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -40 cents.  The mean expectation of thirteen analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from -94 cents to -51 cents per share.
Revenue fell 32.5% to $9.33 million from a year ago; analysts expected $6.04 million. 
Stoke Therapeutics Inc's reported EPS for the quarter was a loss of 93 cents​.
The company reported a quarterly loss of $61.62 million.
Stoke Therapeutics Inc shares had fallen by 11.8% this quarter and lost 9.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 4.5% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Stoke Therapeutics Inc is $44.00, about 34.4% above its last closing price of $28.86
This summary was machine generated from LSEG data August 3 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.80
-0.93
Missed
Mar. 31 2026 
-0.83
-0.79
Beat
Dec. 31 2025 
-0.71
-0.97
Missed
Sep. 30 2025 
-0.57
-0.65
Missed